Related Experiment Videos
Treatment for primary postpartum haemorrhage
1Department of Obstetrics and Gynaecology, Whiston Hospital, Warrington Road, Prescot, Merseyside, UK, L35 5DR. yn5@hotmail.com
The Cochrane Database of Systematic Reviews
|January 22, 2003
Summary
Rectal misoprostol effectively reduced bleeding in postpartum hemorrhage cases. This intervention showed a significant decrease in persistent bleeding and need for further medical treatment compared to standard care.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Maternal Health
Background:
- Primary postpartum hemorrhage (PPH) is a leading cause of maternal mortality globally.
- Effective management of PPH is crucial for reducing maternal morbidity and mortality.
Purpose of the Study:
- To evaluate the efficacy and safety of pharmacological and surgical treatments for PPH.
- To assess rectal misoprostol as a potential intervention for PPH.
Main Methods:
- Systematic review of randomized or quasi-randomized controlled trials.
- Searched Cochrane Pregnancy and Childbirth Group's trials register.
- Included one trial comparing rectal misoprostol with syntometrine and oxytocin infusion.
Main Results:
- Rectal misoprostol significantly reduced persistent bleeding (6% vs. 34%) and the need for additional medical interventions.
- No significant difference was observed in the rates of surgical interventions for intractable hemorrhage.
- The included trial was not powered to assess effects on maternal mortality or hysterectomy rates.
Conclusions:
- Rectal misoprostol (800 micrograms) may serve as an effective first-line treatment for PPH.
- Further research is needed to determine optimal drug combinations, routes, and dosages for PPH management.